Methods for inhibiting conversion of carnitine to trimethylamine (TMA)

US10786479B2 · kind B2 · utility

Assignees

• The Procter & Gamble Company · US
• The Cleveland Clinic Foundation · US

Inventors

• Stanley L. Hazen · Pepper Pike, US
• Jose Carlos Garcia-Garcia · Cincinnati, US
• George Franklin Gerberick · Cincinnati, US
• John August Wos · Cincinnati, US
• David Thomas Stanton · Hamilton, US
• Thomas Alfred Inglin · Loveland, US
• Michael Reilly · Lebanon, US
• Angela Jane Deutsch · Sharonville, US
• Jodie Michele Reed · Loveland, US
• David Blair Cody · Columbus, US

Key dates

• Filing date: Dec 1, 2016
• Grant date: Sep 29, 2020
• Expiry date: Dec 1, 2036

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a method of inhibiting the conversion of carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): Wherein the compound is administered in an amount effective to inhibit conversion of carnitine to TMA in the individual.